$CVM News
Last published 1d ago
- 1d agoCVMCEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer ResearchBusiness WireVIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI’s Dr. Eyal Talor receives second international keynote invitation on Multikine head and neck cancer research.
- 2w agoCVMCEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year SurvivalBusiness WireTarget Population Selection: Biomarker profile – applied prior to treatment of locally advanced disease with no lymph node involvement (N0) and low/zero tumor PD-L1 expression (TPS <10%) or zero identifies patients
- 1mo agoCVMCEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and LaryngologyBusiness WireKeynote presentation at leading head and neck cancer conference will include new findings from CEL-SCI’s landmark Phase 3 study, the largest in the world for its indication CEL-SCI’s patient selection method is a
- 2mo agoCVMCEL-SCI Reports Fiscal Third Quarter 2026 ResultsBusiness WirePeer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer
- 3mo agoCVMCEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration StudyBusiness WireThe published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatment Study concludes
- 3mo agoCVMLeading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer PatientsBusiness WirePeer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory Registration
- 4mo agoCVMCEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerBusiness WirePatient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America The 212-patient confirmatory study is powered at approximately 97% to confirm a previously
- 4mo agoCVMCEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer CareBusiness WireCeremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration Strategic partnership spans regulatory, marketing, distribution, and revenue sharing agreement for
- 4mo agoCVMCEL-SCI Announces Closing of OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of
- 4mo agoCVMCEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry StrategyBusiness WireU.S. Confirmatory Registration Study expected to begin Summer 2026 Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of
- 5mo agoCVMCEL-SCI Corporation Announces Pricing of OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at an offering price
- 5mo agoCVMCEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi ArabiaBusiness WireSaudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030 Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing & Opening Ceremonies Strategic
- 5mo agoCVMCEL-SCI Reports Fiscal Second Quarter 2026 ResultsBusiness WireOn Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026 Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia 50%/50%
- 6mo agoCVMCEL-SCI Announces Closing of Public OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000 shares of its common stock. Each
- 6mo agoCVMCEL-SCI Corporation Announces Pricing of Public OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an
- 6mo agoCVMCEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi ArabiaBusiness Wire50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation Amarox to act as the local regulatory representative and lead all communications with the
- 8mo agoCVMCEL-SCI Reports Fiscal First Quarter 2026 ResultsBusiness WireSet to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and
- 10mo agoCVMCEL-SCI Reports Fiscal 2025 ResultsBusiness WireFiled for Breakthrough Designation for Multikine in Saudi Arabia A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of
- 1y agoCVMCEL-SCI Announces Closing of $10 Million Public OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its offering of 1,111,200 shares of its common stock. Each share of common stock
- 1y agoCVMCEL-SCI Announces Pricing of $10 Million Public OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock. Each
- 1y agoCVMCEL-SCI Announces Proposed Public OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants
- 1y agoCVMCEL-SCI Reports Fiscal Third Quarter 2025 Financial ResultsBusiness WireCEL-SCI to sign partnership agreement in Saudi Arabia—Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following filing for Breakthrough Medicine
- 1y agoCVMCEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA TimelineBusiness WireMemorandum of Understanding (MOU) signed with a leading Saudi Arabian pharma company which submitted the Breakthrough Medicine Designation to the Saudi Food and Drug Authority (SFDA) Increasing interest in CEL-SCI
- 1y agoCVMCEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American RulesBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of
- 1y agoCVMCEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American RulesBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of
- 1y agoCVMCEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck CancerBusiness WireStrong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market Patient access and reimbursement/sale in Saudi Arabia within
- 1y agoCVMFDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer PatientsBusiness WireFDA priority review and approval based on interim results sets a positive precedent, paving the path for future Multikine approval Multikine reduced the risk of death by 66% compared to standard of care in the target
- 1y agoCVMCEL-SCI Announces Closing of Public OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its underwritten public offering of 2,000,000 shares of its common stock at a
- 1y agoCVMCEL-SCI Announces Pricing of Public OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a
- 1y agoCVMCEL-SCI Announces Proposed Public OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants
- 1y agoCVMCEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi ArabiaBusiness WireSaudi Arabia's new Breakthrough Medicine Designation, if granted, would make Multikine available for patient access and commercial use Saudi Food and Drug Authority typically responds to Breakthrough Medicine
- 1y agoCVMCEL-SCI Announces Combination of Common StockBusiness WireCEL-SCI Corporation (NYSE:CVM) announced today that during its annual Shareholder's Meeting on May 19, 2025, a combination was authorized for its outstanding shares of common stock. On May 19, 2025, the Board of
- 1y agoCVMCEL-SCI Reports Fiscal Second Quarter 2025 Financial ResultsBusiness WirePlans to file for approval with Breakthrough Therapy Designation in Saudi Arabia based on completed Phase 3 results CEL-SCI Corporation (NYSE:CVM) today reported financial results for the three months ended March 31,
- 1y agoCVMCEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa MarketBusiness WireConcluded a successful meeting with Saudi Food and Drug Authority CEL-SCI was encouraged to apply for Conditional Approval with Breakthrough Therapy Designation based on data from its concluded Phase 3
- 1y agoONCYCVMOSTXONC+1With Young Adult Cancer on the Rise, New Therapies Spark Investor BuzzPR NewswireEquity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable...
- 1y agoCVMNew Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor ResponsesBusiness WireHead and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of
- 1y agoCVMCEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer PatientsBusiness WireData published in peer-reviewed scientific journal Pathology and Oncology Research Quality of life improvements included reduction in or cessation of pain in the head and neck area, improvement or complete restoration
- 1y agoCVMCEL-SCI Announces Closing of $2.5 Million OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced best-efforts offering of 16,000,000 shares of its common stock
- 1y agoCVMCEL-SCI Announces Pricing of $2.5 Million OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of a best-efforts offering of 16,000,000 shares of its common stock (or pre-funded
- 1y agoCVMCEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of MultikineBusiness WireGrowing body of data on PD-L1 as a cancer biomarker spurs interest Working towards partnership for non-dilutive funding of the final confirmatory head and neck cancer Registration Study CEL-SCI Corporation (NYSE:CVM)
- 1y agoCVMJournal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 ExpressionBusiness WireThe DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely positioned in
- 1y agoCVMCEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer TrialBusiness WireConfirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment Full enrollment expected by Q2 2026 with plans to seek early approval at that time based on early tumor
- 1y agoCVMCEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 WeeksBusiness WireCEL-SCI Corporation (NYSE:CVM) today reported financial results for three months ended December 31, 2024, as well as key recent clinical and corporate developments. "CEL-SCI is very uniquely positioned at this moment
- 1y agoCVMCEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck CancerBusiness WireA 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of start-up preparations - full enrollment expected by Q2 2026 Plans
- 1y agoCVMCEL-SCI Announces Closing of $5 Million OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a cancer immunotherapy company, today announced the closing of its previously announced best-efforts offering of 16,130,000 shares of its common stock (or
- 1y agoCVMCEL-SCI Announces Pricing of $5 Million Public OfferingBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 16,130,000 shares of its common stock (or pre-funded
- 1y agoCVMCEL-SCI Announces Proposed Public Offering of Common StockBusiness WireCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants in lieu
- 1y agoCVMCEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer StudyBusiness WireMultikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery Factors supporting the go-ahead for the 212-person
- 2y agoCVMU.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025Business WireBiomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration Study Patients with low PD-L1 expression treated with Multikine in the target
- 2y agoCVMFDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer PatientsBusiness WireOncologic Drugs Advisory Committee (ODAC) determines risks outweigh benefits in some cancers for frontline immune checkpoint inhibitors, including blockbuster drugs such as Keytruda and Opdivo, in patients with low